[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @Redeye_ Redeye Redeye posts on X about $vitr, $vit, $indt, $canta the most. They currently have XXXXXX followers and 1398 posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::153838561/interactions)  - X Week XXXXXX +163% - X Month XXXXXX +51% - X Months XXXXXXX -XX% - X Year XXXXXXX +15% ### Mentions: XX [#](/creator/twitter::153838561/posts_active)  ### Followers: XXXXXX [#](/creator/twitter::153838561/followers)  - X Week XXXXXX +0.02% - X Month XXXXXX +0.07% - X Months XXXXXX -XXXX% - X Year XXXXXX -XXXX% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::153838561/influencer_rank)  ### Social Influence [#](/creator/twitter::153838561/influence) --- **Social category influence** [cryptocurrencies](/list/cryptocurrencies) [finance](/list/finance) **Social topic influence** [$vitr](/topic/$vitr), [$vit](/topic/$vit), [$indt](/topic/$indt), [$canta](/topic/$canta), [$ctek](/topic/$ctek), [$arise](/topic/$arise), [$ivso](/topic/$ivso), [$gigsek](/topic/$gigsek), [$geno](/topic/$geno), [$bonex](/topic/$bonex) **Top assets mentioned** [Team Vitality Fan Token (VIT)](/topic/$vit) [GenomeFi (GENO)](/topic/$geno) [Bright Union (BRIGHT)](/topic/$bright) [Bware (INFRA)](/topic/$infra) [Aventus (AVT)](/topic/$avt) [Cemex S.A.B. de C.V. (CX)](/topic/$cx) ### Top Social Posts [#](/creator/twitter::153838561/posts) --- Top posts by engagements in the last XX hours "Redeye comments on Invisios Q2-results which saw stronger-than-expected revenue while EBITDA was lower than expected owing to a soft gross margin and somewhat higher-than-expected opex. $IVSO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1946107974008684975) 2025-07-18 07:21:12 UTC 14.5K followers, 1016 engagements "Redeye shares its initial thoughts on CTEKs Q2 report which we think came in slightly softer than expected but still largely in line with our estimates on an aggregated level. $CTEK"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945746120577085547) 2025-07-17 07:23:20 UTC 14.5K followers, XXX engagements "In a new research update Redeye has updated its estimates and valuation for Gaming Innovation Group after the announced acquisition of Askgamblers: $GIGSEK"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1605469715987677185) 2022-12-21 07:46:23 UTC 14.5K followers, XX engagements "Redeye provides its initial take on Vitecs Q2 2025 report which came in considerably below our estimates. $VIT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1943587714567213426) 2025-07-11 08:26:35 UTC 14.5K followers, XXX engagements "Redeye comments on Genovis decision to acquire the remaining XX% of SEQURNA viewing it as a logical synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market. $GENO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1940346251234640071) 2025-07-02 09:46:10 UTC 14.5K followers, 1258 engagements "Redeye provides an update following Iconovos Q2 report. $ICO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945002072392298997) 2025-07-15 06:06:45 UTC 14.5K followers, XXX engagements "Redeye updates its estimates and valuation after Indutrades Q2 2025 report. $INDT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945349912696156366) 2025-07-16 05:08:56 UTC 14.5K followers, 1211 engagements "Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case for Cantargia. $CANTA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1946102709830008923) 2025-07-18 07:00:17 UTC 14.5K followers, 1491 engagements "Redeye gives its initial take on BONESUPPORTs Q2 report. $BONEX"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945022862663815337) 2025-07-15 07:29:21 UTC 14.5K followers, 1376 engagements "GiG's Q4 2022 report came in higher than Redeye's forecast. In addition the company announced that it is initiating a strategic review to split the business into two independent listed companies: $GIGSEK"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1625779968880812033) 2023-02-15 08:52:04 UTC 14.5K followers, XX engagements "Redeye provides a brief comment on the publication of an article in the journal Lung Cancer. $CANTA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945742631310393619) 2025-07-17 07:09:28 UTC 14.5K followers, 2022 engagements "Redeye comments on Cantargias license deal with Otsaka Pharmaceutical which is transformative for the company since it means both CAN10 (the deal's target) and nadunolimab (the main candidate) are now funded. $CANTA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945038105125241017) 2025-07-15 08:29:55 UTC 14.5K followers, 2477 engagements "Redeye provides an update following SSH's Q2 2025 were sales increased by XXX% y/y to EUR5.4m with a EBITDA margin of 7.7%. Operating cash flow was EUR-06m and PrivX grew by 15.1%. $SSH1V"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1946101985062637617) 2025-07-18 06:57:24 UTC 14.5K followers, XXX engagements "Redeye comments on Vitrolife's PGT-A class actions. $VITR"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1897566229730148599) 2025-03-06 08:33:38 UTC 14.5K followers, 1162 engagements "Redeye comments on Vitrolife facing a tough start in 2025 and we expect this to continue during H1 2025. $VITR"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1916742487135182982) 2025-04-28 06:33:14 UTC 14.5K followers, 1025 engagements "Redeye shares its thoughts and fine-tunes its estimates ahead of CTEKs Q2 report which is due Thursday next week (17 July). $CTEK"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1943203382002389139) 2025-07-10 06:59:23 UTC 14.5K followers, XXX engagements "Redeye comments on Invisio ahead of Q2-results (due XX July) where we expect sequential improvement after soft performance in Q1. $IVSO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1943203872991834406) 2025-07-10 07:01:20 UTC 14.5K followers, XXX engagements "Redeye comments on IRLABs announcement of a fully guaranteed SEK 136m rights issue aimed at advancing its clinical pipeline and strengthening its capital structure. $IRLAB"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1937511413401964609) 2025-06-24 14:01:32 UTC 14.5K followers, XXX engagements "Redeye provides its first take on Cellavisions Q2 report 2025 published this morning. $CEVI"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1946106842435727842) 2025-07-18 07:16:42 UTC 14.5K followers, XXX engagements "Redeye comments on Avtech's reported preliminary Q2 2025 net sales of SEK11.8m and an EBITDA of SEK5.5m marking year-on-year growth of XX% for both metrics and an EBITDA margin of 42%. $AVT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1942100803684028912) 2025-07-07 05:58:08 UTC 14.5K followers, 1098 engagements "Redeye comments on Vitrolife facing a tough start in 2025 and we expect this to continue during H1 2025. $VITR"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1915365110161281184) 2025-04-24 11:20:02 UTC 14.5K followers, XXX engagements "Redeye interviews Hansa Biopharma's CEO Rene Aguiar-Lucander after her very intense first two months with the company. $HNSA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1938571246964494789) 2025-06-27 12:12:56 UTC 14.5K followers, 11.8K engagements "Redeye comments on Hansa being in a better position to support its main value drivers engage in strategic priorities and potentially extend the number of commercial and clinical partners over the next 6-12 months. $HNSA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945746632798019639) 2025-07-17 07:25:22 UTC 14.5K followers, XXX engagements "Redeye comments on BrightBids Q1 report with numbers aligning with the preliminary figures. $BRIGHT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1920353703933936007) 2025-05-08 05:42:56 UTC 14.5K followers, 1017 engagements "Redeye provides its initial take on Lifcos Q2 2025 report which came in below our estimates. $LIFCO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1944640209951375476) 2025-07-14 06:08:50 UTC 14.5K followers, 1665 engagements "Redeye returns with a more in-depth take on Bonesupport's Q2 report. $BONEX"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945365138757878112) 2025-07-16 06:09:26 UTC 14.5K followers, 1289 engagements "Redeye interviews Vitecs CEO Olle Backman. We discuss the companys Q2 2025 report this quarters tough comparables for Enova and prospects for H2 2025. $VIT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1943669096618303808) 2025-07-11 13:49:58 UTC 14.5K followers, 1150 engagements "Vitrolife is trading below Redeye's Base Case. We had a chat with Redeye's analyst and discussed the outlook for 2025 what can drive the share price closer to our Base Case and more. This is a premium article included in our paid plans from SEK 99/month. $VITR"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1909537569345257547) 2025-04-08 09:23:28 UTC 14.5K followers, 1317 engagements "Redeye comments on CombinedXs Q2 report showing negative growth and lower margins than expected. On the positive note the underlying data looks relatively solid. $CX"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945823834776477869) 2025-07-17 12:32:08 UTC 14.5K followers, XXX engagements "Redeye comments on Synact Pharma's conversion of warrants and Cantargia's deal yesterday. $SYNACT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945395235485323389) 2025-07-16 08:09:02 UTC 14.5K followers, 1070 engagements "Vitec Software is trading below Redeye's Base Case. We had a chat with Redeye's where we discussed the recent quarterly report what makes Vitec stand out from its peers and more. This is a premium article included in our paid plans from SEK 99/month. $VIT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1919774140455653447) 2025-05-06 15:19:57 UTC 14.5K followers, 1109 engagements "Redeye comments on this morning's press release from Arise stating that it has reached an agreement with Foresight regarding the earn-out payment for Klvallen of approx. EUR30m. $ARISE"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945395532240769448) 2025-07-16 08:10:13 UTC 14.5K followers, 1185 engagements "Redeye nudges down its estimates and valuation following Lifcos Q2 2025 report. $LIFCO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945002330421633498) 2025-07-15 06:07:46 UTC 14.5K followers, 1086 engagements "Redeye recently initiated coverage of Indutrade and we interviewed analyst Christian Binder who talked us through the investment case. $INDT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1922535498939068604) 2025-05-14 06:12:36 UTC 14.5K followers, XXX engagements "Redeye provides its initial take on Indutrades Q2 2025 report which came in below our estimates. $INDT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945009788619833722) 2025-07-15 06:37:24 UTC 14.5K followers, 1182 engagements "Redeye comments on Infracom confirming yesterday that Bredband2 is the underlying investment for its total return swap (TRS). $INFRA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1940333555672137939) 2025-07-02 08:55:43 UTC 14.5K followers, 1429 engagements "Redeye retains its Base Case for BrightBid and makes minor forecast adjustments following the full Q1 report with numbers aligning with the preliminary. $BRIGHT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1920732754443976921) 2025-05-09 06:49:08 UTC 14.5K followers, XXX engagements "Redeye will have a live update with Cantargia at XXXXX in which we will interview CEO Damian Marron about the deal with Otsuka Pharmaceutical. $CANTA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945085684395499759) 2025-07-15 11:38:59 UTC 14.5K followers, 1689 engagements "Redeye interviews Calliditas' CEO Rene Aguiar-Lucander after securing full FDA approval for Tarpeyo. $CALTX"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1738095137996017664) 2023-12-22 07:12:27 UTC 14.5K followers, 3129 engagements "Redeye lowers its estimates and valuation following Vitecs Q2 2025 report. $VIT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1944639786825683139) 2025-07-14 06:07:09 UTC 14.5K followers, XXX engagements "Redeye states that the Q2 report came in broadly in line with our expectations with a high YoY net sales growth of XX% and even as high as XX% FX-adjusted. $SIVE"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945745540798349428) 2025-07-17 07:21:01 UTC 14.5K followers, XXX engagements "Redeye comments on Vitrolife facing a tough 2025 and we expect this to continue during H2 2025 at best at a fading rate. $VITR"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1945823593377521827) 2025-07-17 12:31:10 UTC 14.5K followers, XXX engagements "Redeye updates on InfraCom following Telias bid for Bredband2 at SEK3.25 per share InfraCom has agreed to tender its shares. $INFRA"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1946108165227008477) 2025-07-18 07:21:58 UTC 14.5K followers, 1201 engagements "Redeye comments on Arises Q2 report which saw higher production than expected driving the segment's earnings generation. $ARISE"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1946147738082480445) 2025-07-18 09:59:13 UTC 14.5K followers, XXX engagements "Indutrade is trading below Redeye's Base Case. We had a chat with our analyst where we discussed the factors driving Indutrade's high success rate in past M&A deals preservation of Indutrade's decentralised culture and more. This is a premium article included in our paid plans from SEK 99/month. $INDT"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1934894384975131014) 2025-06-17 08:42:24 UTC 14.5K followers, XXX engagements "Redeye updates its production estimates ahead of Arise's Q2 report on Friday next week (18 July). $ARISE"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1943554447763739048) 2025-07-11 06:14:24 UTC 14.5K followers, XXX engagements "Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates across the board. $GENO"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1930149691133411601) 2025-06-04 06:28:41 UTC 14.5K followers, 1126 engagements "Redeye briefly comments on CTEKs new financial targets that were presented this morning ahead of todays capital markets day (CEST 13.30). $CTEK"  [@Redeye_](/creator/x/Redeye_) on [X](/post/tweet/1925491414378430843) 2025-05-22 09:58:21 UTC 14.5K followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@Redeye_ Redeye
Redeye posts on X about $vitr, $vit, $indt, $canta the most. They currently have XXXXXX followers and 1398 posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +163%
- X Month XXXXXX +51%
- X Months XXXXXXX -XX%
- X Year XXXXXXX +15%
Mentions: XX #
Followers: XXXXXX #
- X Week XXXXXX +0.02%
- X Month XXXXXX +0.07%
- X Months XXXXXX -XXXX%
- X Year XXXXXX -XXXX%
CreatorRank: XXXXXXXXX #
Social Influence #
Social category influence cryptocurrencies finance
Social topic influence $vitr, $vit, $indt, $canta, $ctek, $arise, $ivso, $gigsek, $geno, $bonex
Top assets mentioned Team Vitality Fan Token (VIT) GenomeFi (GENO) Bright Union (BRIGHT) Bware (INFRA) Aventus (AVT) Cemex S.A.B. de C.V. (CX)
Top Social Posts #
Top posts by engagements in the last XX hours
"Redeye comments on Invisios Q2-results which saw stronger-than-expected revenue while EBITDA was lower than expected owing to a soft gross margin and somewhat higher-than-expected opex. $IVSO"
@Redeye_ on X 2025-07-18 07:21:12 UTC 14.5K followers, 1016 engagements
"Redeye shares its initial thoughts on CTEKs Q2 report which we think came in slightly softer than expected but still largely in line with our estimates on an aggregated level. $CTEK" @Redeye_ on X 2025-07-17 07:23:20 UTC 14.5K followers, XXX engagements
"In a new research update Redeye has updated its estimates and valuation for Gaming Innovation Group after the announced acquisition of Askgamblers: $GIGSEK" @Redeye_ on X 2022-12-21 07:46:23 UTC 14.5K followers, XX engagements
"Redeye provides its initial take on Vitecs Q2 2025 report which came in considerably below our estimates. $VIT" @Redeye_ on X 2025-07-11 08:26:35 UTC 14.5K followers, XXX engagements
"Redeye comments on Genovis decision to acquire the remaining XX% of SEQURNA viewing it as a logical synergistic move that leverages its growing net cash and adds exposure to the sizable and growing genomics market. $GENO" @Redeye_ on X 2025-07-02 09:46:10 UTC 14.5K followers, 1258 engagements
"Redeye provides an update following Iconovos Q2 report. $ICO" @Redeye_ on X 2025-07-15 06:06:45 UTC 14.5K followers, XXX engagements
"Redeye updates its estimates and valuation after Indutrades Q2 2025 report. $INDT" @Redeye_ on X 2025-07-16 05:08:56 UTC 14.5K followers, 1211 engagements
"Redeye comments on the negative topline data in the TRIFOUR study and provides a new base case for Cantargia. $CANTA" @Redeye_ on X 2025-07-18 07:00:17 UTC 14.5K followers, 1491 engagements
"Redeye gives its initial take on BONESUPPORTs Q2 report. $BONEX" @Redeye_ on X 2025-07-15 07:29:21 UTC 14.5K followers, 1376 engagements
"GiG's Q4 2022 report came in higher than Redeye's forecast. In addition the company announced that it is initiating a strategic review to split the business into two independent listed companies: $GIGSEK" @Redeye_ on X 2023-02-15 08:52:04 UTC 14.5K followers, XX engagements
"Redeye provides a brief comment on the publication of an article in the journal Lung Cancer. $CANTA" @Redeye_ on X 2025-07-17 07:09:28 UTC 14.5K followers, 2022 engagements
"Redeye comments on Cantargias license deal with Otsaka Pharmaceutical which is transformative for the company since it means both CAN10 (the deal's target) and nadunolimab (the main candidate) are now funded. $CANTA" @Redeye_ on X 2025-07-15 08:29:55 UTC 14.5K followers, 2477 engagements
"Redeye provides an update following SSH's Q2 2025 were sales increased by XXX% y/y to EUR5.4m with a EBITDA margin of 7.7%. Operating cash flow was EUR-06m and PrivX grew by 15.1%. $SSH1V" @Redeye_ on X 2025-07-18 06:57:24 UTC 14.5K followers, XXX engagements
"Redeye comments on Vitrolife's PGT-A class actions. $VITR" @Redeye_ on X 2025-03-06 08:33:38 UTC 14.5K followers, 1162 engagements
"Redeye comments on Vitrolife facing a tough start in 2025 and we expect this to continue during H1 2025. $VITR" @Redeye_ on X 2025-04-28 06:33:14 UTC 14.5K followers, 1025 engagements
"Redeye shares its thoughts and fine-tunes its estimates ahead of CTEKs Q2 report which is due Thursday next week (17 July). $CTEK" @Redeye_ on X 2025-07-10 06:59:23 UTC 14.5K followers, XXX engagements
"Redeye comments on Invisio ahead of Q2-results (due XX July) where we expect sequential improvement after soft performance in Q1. $IVSO" @Redeye_ on X 2025-07-10 07:01:20 UTC 14.5K followers, XXX engagements
"Redeye comments on IRLABs announcement of a fully guaranteed SEK 136m rights issue aimed at advancing its clinical pipeline and strengthening its capital structure. $IRLAB" @Redeye_ on X 2025-06-24 14:01:32 UTC 14.5K followers, XXX engagements
"Redeye provides its first take on Cellavisions Q2 report 2025 published this morning. $CEVI" @Redeye_ on X 2025-07-18 07:16:42 UTC 14.5K followers, XXX engagements
"Redeye comments on Avtech's reported preliminary Q2 2025 net sales of SEK11.8m and an EBITDA of SEK5.5m marking year-on-year growth of XX% for both metrics and an EBITDA margin of 42%. $AVT" @Redeye_ on X 2025-07-07 05:58:08 UTC 14.5K followers, 1098 engagements
"Redeye comments on Vitrolife facing a tough start in 2025 and we expect this to continue during H1 2025. $VITR" @Redeye_ on X 2025-04-24 11:20:02 UTC 14.5K followers, XXX engagements
"Redeye interviews Hansa Biopharma's CEO Rene Aguiar-Lucander after her very intense first two months with the company. $HNSA" @Redeye_ on X 2025-06-27 12:12:56 UTC 14.5K followers, 11.8K engagements
"Redeye comments on Hansa being in a better position to support its main value drivers engage in strategic priorities and potentially extend the number of commercial and clinical partners over the next 6-12 months. $HNSA" @Redeye_ on X 2025-07-17 07:25:22 UTC 14.5K followers, XXX engagements
"Redeye comments on BrightBids Q1 report with numbers aligning with the preliminary figures. $BRIGHT" @Redeye_ on X 2025-05-08 05:42:56 UTC 14.5K followers, 1017 engagements
"Redeye provides its initial take on Lifcos Q2 2025 report which came in below our estimates. $LIFCO" @Redeye_ on X 2025-07-14 06:08:50 UTC 14.5K followers, 1665 engagements
"Redeye returns with a more in-depth take on Bonesupport's Q2 report. $BONEX" @Redeye_ on X 2025-07-16 06:09:26 UTC 14.5K followers, 1289 engagements
"Redeye interviews Vitecs CEO Olle Backman. We discuss the companys Q2 2025 report this quarters tough comparables for Enova and prospects for H2 2025. $VIT" @Redeye_ on X 2025-07-11 13:49:58 UTC 14.5K followers, 1150 engagements
"Vitrolife is trading below Redeye's Base Case. We had a chat with Redeye's analyst and discussed the outlook for 2025 what can drive the share price closer to our Base Case and more. This is a premium article included in our paid plans from SEK 99/month. $VITR" @Redeye_ on X 2025-04-08 09:23:28 UTC 14.5K followers, 1317 engagements
"Redeye comments on CombinedXs Q2 report showing negative growth and lower margins than expected. On the positive note the underlying data looks relatively solid. $CX" @Redeye_ on X 2025-07-17 12:32:08 UTC 14.5K followers, XXX engagements
"Redeye comments on Synact Pharma's conversion of warrants and Cantargia's deal yesterday. $SYNACT" @Redeye_ on X 2025-07-16 08:09:02 UTC 14.5K followers, 1070 engagements
"Vitec Software is trading below Redeye's Base Case. We had a chat with Redeye's where we discussed the recent quarterly report what makes Vitec stand out from its peers and more. This is a premium article included in our paid plans from SEK 99/month. $VIT" @Redeye_ on X 2025-05-06 15:19:57 UTC 14.5K followers, 1109 engagements
"Redeye comments on this morning's press release from Arise stating that it has reached an agreement with Foresight regarding the earn-out payment for Klvallen of approx. EUR30m. $ARISE" @Redeye_ on X 2025-07-16 08:10:13 UTC 14.5K followers, 1185 engagements
"Redeye nudges down its estimates and valuation following Lifcos Q2 2025 report. $LIFCO" @Redeye_ on X 2025-07-15 06:07:46 UTC 14.5K followers, 1086 engagements
"Redeye recently initiated coverage of Indutrade and we interviewed analyst Christian Binder who talked us through the investment case. $INDT" @Redeye_ on X 2025-05-14 06:12:36 UTC 14.5K followers, XXX engagements
"Redeye provides its initial take on Indutrades Q2 2025 report which came in below our estimates. $INDT" @Redeye_ on X 2025-07-15 06:37:24 UTC 14.5K followers, 1182 engagements
"Redeye comments on Infracom confirming yesterday that Bredband2 is the underlying investment for its total return swap (TRS). $INFRA" @Redeye_ on X 2025-07-02 08:55:43 UTC 14.5K followers, 1429 engagements
"Redeye retains its Base Case for BrightBid and makes minor forecast adjustments following the full Q1 report with numbers aligning with the preliminary. $BRIGHT" @Redeye_ on X 2025-05-09 06:49:08 UTC 14.5K followers, XXX engagements
"Redeye will have a live update with Cantargia at XXXXX in which we will interview CEO Damian Marron about the deal with Otsuka Pharmaceutical. $CANTA" @Redeye_ on X 2025-07-15 11:38:59 UTC 14.5K followers, 1689 engagements
"Redeye interviews Calliditas' CEO Rene Aguiar-Lucander after securing full FDA approval for Tarpeyo. $CALTX" @Redeye_ on X 2023-12-22 07:12:27 UTC 14.5K followers, 3129 engagements
"Redeye lowers its estimates and valuation following Vitecs Q2 2025 report. $VIT" @Redeye_ on X 2025-07-14 06:07:09 UTC 14.5K followers, XXX engagements
"Redeye states that the Q2 report came in broadly in line with our expectations with a high YoY net sales growth of XX% and even as high as XX% FX-adjusted. $SIVE" @Redeye_ on X 2025-07-17 07:21:01 UTC 14.5K followers, XXX engagements
"Redeye comments on Vitrolife facing a tough 2025 and we expect this to continue during H2 2025 at best at a fading rate. $VITR" @Redeye_ on X 2025-07-17 12:31:10 UTC 14.5K followers, XXX engagements
"Redeye updates on InfraCom following Telias bid for Bredband2 at SEK3.25 per share InfraCom has agreed to tender its shares. $INFRA" @Redeye_ on X 2025-07-18 07:21:58 UTC 14.5K followers, 1201 engagements
"Redeye comments on Arises Q2 report which saw higher production than expected driving the segment's earnings generation. $ARISE" @Redeye_ on X 2025-07-18 09:59:13 UTC 14.5K followers, XXX engagements
"Indutrade is trading below Redeye's Base Case. We had a chat with our analyst where we discussed the factors driving Indutrade's high success rate in past M&A deals preservation of Indutrade's decentralised culture and more. This is a premium article included in our paid plans from SEK 99/month. $INDT" @Redeye_ on X 2025-06-17 08:42:24 UTC 14.5K followers, XXX engagements
"Redeye updates its production estimates ahead of Arise's Q2 report on Friday next week (18 July). $ARISE" @Redeye_ on X 2025-07-11 06:14:24 UTC 14.5K followers, XXX engagements
"Redeye updates its outlook on Genovis following a Q1 report coming in slightly above our estimates across the board. $GENO" @Redeye_ on X 2025-06-04 06:28:41 UTC 14.5K followers, 1126 engagements
"Redeye briefly comments on CTEKs new financial targets that were presented this morning ahead of todays capital markets day (CEST 13.30). $CTEK" @Redeye_ on X 2025-05-22 09:58:21 UTC 14.5K followers, XXX engagements